N/A
N=377
Assessment of Giant Cell Arteritis Medical Practices in France
Giant Cell Arteritis
Bottom Line
View on ClinicalTrials.gov: NCT03658889 ↗Enrolled (actual)
377
Serious AEs
—
Results posted
May 2020
Primary outcome: Primary: Patient Journey : Physicians Who Referred the Patient — 171; 31; 21; 17 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 50+ yrs
- Sex
- All
- Sponsor
- Chugai Pharma France
- Primary completion
- Nov 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Patient Journey : Physicians Who Referred the Patient |
171; 31; 21; 17; 13; 15 | — |
| PRIMARY Patient Journey : Physician Encountered by the Patient at Least One Time Since the First Events Related to GCA |
260; 88; 38; 54; 59; 42 | — |
| PRIMARY Patient Journey : Time to GCA Diagnosis |
1.00 | — |
| PRIMARY GCA Diagnostic Method |
154; 266; 249; 91; 20; 74 | — |
| PRIMARY GCA Treatments Since Diagnosis : Glucocorticoids Since Diagnosis |
9.00; 4305.00 | — |
| PRIMARY GCA Treatments Since Diagnosis: Glucocorticoids at Inclusion |
273 | — |
| PRIMARY GCA Treatments Since Diagnosis: Immunosuppressants Stopped Before Inclusion |
2; 1; 0; 1; 25; 0 | — |
| PRIMARY GCA Treatments Since Diagnosis: Immunosuppressants Ongoing at Inclusion |
0; 0; 0; 0; 35; 0 | — |
| PRIMARY GCA Treatments Since Diagnosis: Targeted Biologic Therapies Stopped Before Inclusion |
1; 0; 0; 0; 9; 0 | — |
| PRIMARY GCA Treatments Since Diagnosis: Targeted Biologic Therapies Ongoing at Inclusion |
0; 0; 0; 1; 44; 0 | — |
| SECONDARY Comorbidities Related to GCs |
5; 2; 9; 4; 2; 10 | — |
| SECONDARY Treatments in Patients With Comorbidities Related to GCs |
98 | — |
| SECONDARY Proportion of Incident Patients |
39 | — |
| SECONDARY Proportion of Prevalent Patients |
267 | — |
| SECONDARY GCA Duration |
13.00; 15.00; 0.60 | — |
| SECONDARY GCA Initial Presentation |
271; 148; 108; 129; 227 | — |
| SECONDARY GCA Clinical Form |
69; 32; 11; 6; 4 | — |
| SECONDARY Patients With GCA Complications |
48 | — |
| SECONDARY Global Arteritis Activity |
18.00; 4.00 | — |
| SECONDARY Patient Reported Outcome (PRO) Scores: Short Form-36 (SF-36) Questionnaire |
70.00; 56.25; 62.00; 57.00; 66.67; 50.00 | — |
| SECONDARY PRO Scores: EQ5D-3L Questionnaire |
0.79; 69.00 | — |
| SECONDARY PRO Scores: FACIT-Fatigue Questionnaire |
39.00 | — |
| SECONDARY Physician Medical Specialty |
56; 12; 1 | — |
| SECONDARY Physician Number of Years of Practice |
13.00 | — |
| SECONDARY Physician Type of Practice |
39; 30 | — |
| SECONDARY Physician Characteristics: Number of GCA Diagnosis |
2; 17; 12; 16; 21 | — |
Summary
The purpose of this study is to describe medical practices in patients with GCA in terms of patient journey, diagnostic methods and specific GCA treatments since diagnosis.
Eligibility Criteria
Inclusion Criteria
- At least 50 years old.
- Suffering from GCA as per investigator judgement, newly diagnosed or not.
- Starting or under treatment for GCA.
- Informed verbally and in writing about this study and not objecting to their data being electronically processed or subjected to data quality control.
Non-inclusion Criteria:
- Unable to consent
- Participation to a randomised controlled clinical trial
Data sourced from ClinicalTrials.gov (NCT03658889). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.